These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22770604)

  • 41. MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena.
    Quarmby V; Phung QT; Lill JR
    Expert Rev Proteomics; 2018 Sep; 15(9):733-748. PubMed ID: 30198337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins?
    Sauerborn M; Schellekens H
    Curr Opin Biotechnol; 2009 Dec; 20(6):715-21. PubMed ID: 19892544
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals.
    Wadhwa M; Gaines-Das R; Thorpe R; Mire-Sluis A
    Dev Biol (Basel); 2005; 122():155-70. PubMed ID: 16375260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.
    Richard J; Prang N
    IDrugs; 2010 Aug; 13(8):550-8. PubMed ID: 20721826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters.
    Barbosa MD
    Drug Discov Today; 2011 Apr; 16(7-8):345-53. PubMed ID: 21300174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity assessment during the development of protein therapeutics.
    Rosenberg AS; Sauna ZE
    J Pharm Pharmacol; 2018 May; 70(5):584-594. PubMed ID: 28872677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space.
    Wakshull E; Quarmby V; Mahler HC; Rivers H; Jere D; Ramos M; Szczesny P; Bechtold-Peters K; Masli S; Gupta S
    AAPS J; 2017 Nov; 19(6):1656-1668. PubMed ID: 28795351
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biotherapeutics and immunogenicity: ophthalmic perspective.
    Sharma A; Kumar N; Kuppermann BD; Bandello F; Loewenstein A
    Eye (Lond); 2019 Sep; 33(9):1359-1361. PubMed ID: 30967643
    [No Abstract]   [Full Text] [Related]  

  • 50. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses.
    Barbosa MD; Celis E
    Drug Discov Today; 2007 Aug; 12(15-16):674-81. PubMed ID: 17706550
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.
    van Brummelen EM; Ros W; Wolbink G; Beijnen JH; Schellens JH
    Oncologist; 2016 Oct; 21(10):1260-1268. PubMed ID: 27440064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of immunogenicity of therapeutic proteins: validity of computational tools.
    Bryson CJ; Jones TD; Baker MP
    BioDrugs; 2010 Feb; 24(1):1-8. PubMed ID: 20055528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibodies against erythropoietin and other protein-based therapeutics: an overview.
    Kromminga A; Schellekens H
    Ann N Y Acad Sci; 2005 Jun; 1050():257-65. PubMed ID: 16014541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of biotherapeutics-an overview.
    Subramanyam M
    J Immunotoxicol; 2006 Sep; 3(3):151-6. PubMed ID: 18958695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing the Immunogenicity of Biopharmaceuticals.
    Pineda C; Castañeda Hernández G; Jacobs IA; Alvarez DF; Carini C
    BioDrugs; 2016 Jun; 30(3):195-206. PubMed ID: 27097915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implications of available design space for identification of non-immunogenic protein therapeutics.
    Lee SC
    Biomed Microdevices; 2010 Apr; 12(2):283-6. PubMed ID: 20012559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility.
    Wadhwa M; Knezevic I; Kang HN; Thorpe R
    Biologicals; 2015 Sep; 43(5):298-306. PubMed ID: 26144595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Editorial: Immunogenicity of Proteins Used as Therapeutics.
    Sauna ZE; Richards SM; Maillere B; Jury EC; Rosenberg AS
    Front Immunol; 2020; 11():614856. PubMed ID: 33193460
    [No Abstract]   [Full Text] [Related]  

  • 60. Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction.
    Koren E; Zuckerman LA; Mire-Sluis AR
    Curr Pharm Biotechnol; 2002 Dec; 3(4):349-60. PubMed ID: 12463417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.